Why the study?
Does torasemide reduce systolic blood pressure and increase intracellular cAMP and cGMP in the aorta compared to frusemide in renal hypertensive rats?
Does torasemide reduce systolic blood pressure and increase intracellular cAMP and cGMP in the aorta compared to frusemide in renal hypertensive rats?
Torasemide exhibits a greater antihypertensive effect than furosemide in renal hypertensive rats, potentially mediated by an increase in aortic cAMP and cGMP.
Answers are grounded in this paper and cite their sources.
Supports hypothesis of torasemide's vascular cAMP/cGMP effects in this model; leaves open any human translation.
Repeated oral administration of the novel loop diuretic torasemide (3 mg kg-1) and frusemide (30 mg kg-1) for 7 days, elicited a significant fall in the systolic blood pressure in the one-kidney, one-clip Goldblatt renal hypertensive rat (RHR). The hypotensive action was greater in the torasemide group than in the frusemide group. Furthermore torasemide increased intracellular cAMP and cGMP content in aorta of RHR. Frusemide caused no effect. It is hypothesized that the increase in adenosine- or guanosine-nucleotides is involved in the antihypertensive action of torasemide, but not in that of frusemide.
No takes yet. Share an insight, caveat, or question.
Yamanaga et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: